Introduction
============

Cervical Cancer (CC) is a highly aggressive tumor and is one of the leading causes of cancer-associated mortality in women, with an estimated 570,000 new cases and 311,000 deaths in 2018 worldwide ([@b1-ol-0-0-11439]). Women with CC are considered to have a lower quality of life ([@b2-ol-0-0-11439]). The progression of CC, from normal cervical mucosal epithelium to cervical intraepithelial neoplasia (CIN) grade 1, 2, and 3, to CC ([@b3-ol-0-0-11439]) is associated with persistent high-risk human papillomavirus (HPV) infection ([@b4-ol-0-0-11439]). Furthermore, a number of risk factors, including early sexual activity ([@b5-ol-0-0-11439]), multiple sexual partners ([@b6-ol-0-0-11439]), long-term use of oral contraceptives ([@b7-ol-0-0-11439]), genetic factors \[active oncogenes, including PIK3CA ([@b8-ol-0-0-11439]), ATAD2 ([@b9-ol-0-0-11439]) and CRNDE ([@b10-ol-0-0-11439]); tumor suppressor genes, including p53 ([@b11-ol-0-0-11439]), Ras association domain family 1 isoform A ([@b12-ol-0-0-11439]) and NOL7 ([@b13-ol-0-0-11439])\], tobacco use \[current smoker, started smoking age ≤15 years, smoking duration ≥30 years, ≥20 cigarettes/day ([@b14-ol-0-0-11439])\] and other viral infections (such as HIV, herpes simplex virus (HSV) type II and bacterial infections caused by *Chlamydia trachomatis*) ([@b15-ol-0-0-11439]) have been associated with CC progression.

HPV infection plays a leading role in CC ([@b16-ol-0-0-11439]). The DNA of HPV integrates into the host cell genome \[HPV16: q21-q31 of chromosome no. 13; HPV18: q24 of chromosome no. 8 ([@b17-ol-0-0-11439])\], disrupts the open reading frame and causes overexpression of E6 and E7 genes ([@b18-ol-0-0-11439]). It has been verified that E6 and E7 exert carcinogenic effects by binding to the cell cycle regulators, p53 and retinoblastoma (Rb) ([@b19-ol-0-0-11439]). While E6 and E7 proteins are upregulated, E6 can interact with its associated protein \[E6-associated protein, E6AP ([@b20-ol-0-0-11439])\] to form a complex and bind to p53. This binding hydrolyzes p53 and results in the loss of p53-induced negative regulation of cell proliferation, thereby leading to unchecked cellular proliferation and malignant transformation ([@b21-ol-0-0-11439]). E7 has a high affinity for Rb, which controls the cell cycle. Binding of E7 to Rb can dissociate the Rb-E2F complex, thus releasing E2F to exert its role as a transcription factor, which leads to an uncontrolled cell cycle and cellular immortalization ([@b22-ol-0-0-11439],[@b23-ol-0-0-11439]). Furthermore, centrosomes are central regulators of mitosis that are often increased in numbers in cancer cells ([@b24-ol-0-0-11439]). A previous study indicated that an abnormally increased number of centrosomes is associated with structural chromosomal abnormality in cervical lesions with high risk of HPV infection ([@b25-ol-0-0-11439]). Duensing and Münger ([@b26-ol-0-0-11439]) reported that abnormal number of centrosomes and associated spindle mitotic abnormality can be found in cells infected by the high-risk HPV16 E6 and E7 proteins, but not in cells infected by the low-risk HPV6. Although numerous experimental studies on genes \[HPV16 L1 protein ([@b27-ol-0-0-11439]), sonic hedgehog ([@b28-ol-0-0-11439]) and FGFR4 ([@b29-ol-0-0-11439])\], and signaling pathways \[Wnt/β-catenin signaling pathway ([@b30-ol-0-0-11439]), adenosinergic pathway ([@b31-ol-0-0-11439]) and ERK signal transduction ([@b32-ol-0-0-11439])\], as well as bioinformatics analyses have focused on microRNAs ([@b33-ol-0-0-11439]) and genes ([@b34-ol-0-0-11439]) associated with CC, and have provided an understanding of the pathophysiological mechanisms of the disease over the last decade, the underlying molecular mechanisms remain unclear.

The development of CC occurs over a number of years and its complexity presents clinical challenges in patients screening and treatment. Currently, The Bethesda System ([@b35-ol-0-0-11439]), which is a tool that is used to report Pap smear results for cervical cytologic diagnoses, provides useful data that allows research into the epidemiology, biology and pathology of cervical lesions; however, its diagnostic value remains poor ([@b36-ol-0-0-11439]). Instead, direct biopsy remains the gold standard for diagnosis. Nevertheless, invasive examinations may cause adverse psychological effects, including anxiety, depression or distress ([@b37-ol-0-0-11439]). Surgery, chemotherapy and radiotherapy ([@b38-ol-0-0-11439]) are the three major therapeutic strategies in the treatment of CC; however, their uses may be limited for various reasons. Surgery may be limited by the status and stage of patients, including late stage or tolerance to anesthesia ([@b39-ol-0-0-11439]), whereas chemotherapy is limited due to the lack of sensitivity and the development of drug resistance ([@b40-ol-0-0-11439]). In addition, radiotherapy can be limited by the maximum tolerated dose to adjacent normal tissues ([@b41-ol-0-0-11439]). Thus, it is essential to understand the underlying molecular mechanisms in the initiation and development of CC, in order to develop methods for its accurate diagnosis and effective treatment. A number of studies have reported that multiple genes \[CXCL12 ([@b42-ol-0-0-11439]), FGFR4 ([@b29-ol-0-0-11439]) and SHH ([@b43-ol-0-0-11439])\], proteins \[cyclin D1 ([@b44-ol-0-0-11439]), FOXO1 ([@b45-ol-0-0-11439]) and BASP1 ([@b46-ol-0-0-11439])\] and pathways \[Toll-like signaling pathway ([@b47-ol-0-0-11439]), VEGF signaling pathway ([@b48-ol-0-0-11439]) and Wnt signaling pathway ([@b30-ol-0-0-11439])\] are involved in the natural progression of CC; however, few studies have investigated the fundamental pathological molecular mechanisms in the progression of CC (from normal, to CIN1, CIN2, CIN3, to cancer). Thus, the specific pathological processes remain unclear.

The present study provided a systematic investigation of the development of CC and further understanding of the associations between the four phases of CC progression, and thus revealed additional targets for the detection and treatment of CC. A flow diagram of the present study is presented in [Fig. 1](#f1-ol-0-0-11439){ref-type="fig"}.

Materials and methods
=====================

### Identification of differentially expressed genes (DEGs)

The CC gene expression profile in the GSE63514 dataset, acquired using the GPL570 platform (Affymetrix Human Genome U133 Plus 2.0 Array) provided by den Boon in 2015 ([@b49-ol-0-0-11439]), was downloaded from the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>). The profile contained 128 cervical specimens, including: Normal (n=24), CIN1 (n=14), CIN2 (n=22), CIN3 (n=40) and cancer (n=28) samples. All samples were divided into four phases as follows: Phase I, normal to CIN1; phase II, CIN1 to CIN2; phase III, CIN2 to CIN3 and phase IV, CIN3 to cancer, and GEO2R tools (<https://www.ncbi.nlm.nih.gov/geo/geo2r/>) ([@b50-ol-0-0-11439]) within the limma package version 3.26.8 ([@b51-ol-0-0-11439]) were used to screen the DEGs at the four phases. The criteria fold change (FC) of expression \>2 and P\<0.05 were used to identify DEGs.

### Identification of hub genes

The Search Tool for the Retrieval of Interacting Genes (STRING) database ([@b52-ol-0-0-11439]) and Cytoscape software (version 3.5.1) ([@b53-ol-0-0-11439]) were used to identify the hub genes in the four phases. The PPI network was constructed by searching for gene symbols and the minimum required interaction score was set at 0.7, to ensure high confidence in the results. The nodes that not connect to the major network were removed to decrease the error detection rate. CytoHubba ([@b54-ol-0-0-11439]), a plug-in for Cytoscape software, was used to investigate notable nodes in the interactome network using 12 topological algorithms, including Degree, Edge Percolated Component, Maximum Neighborhood Component, Density of Maximum Neighborhood Component and Maximal Clique Centrality, and centralities based on shortest paths, such as Bottleneck, EcCentricity, Closeness, Radiality, Betweenness, Clustering Coefficient and Stress. The genes that ranked in the top 10 for each topological algorithm were extracted and the duplication of each gene was calculated. Genes duplicated \<2 times were excluded, in order to guarantee that the genes were associated with CC. The remaining genes were considered as hub genes in the four phases.

### Functional enrichment analyses of GO and pathways

The functional features of the genes associated with the four phases were examined using WebGestalt ([@b55-ol-0-0-11439]) and ToppGene ([@b56-ol-0-0-11439]). In WebGestalt, over-representation analysis was selected as the enrichment method, Biological Process in GO as the functional database, gene symbol as the gene ID type and genome as the reference set for enrichment analysis. In ToppGene, two frequently used databases, Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.kegg.jp/>) and BioCarta (<https://www.biocarta.com/>), were utilized to perform pathway enrichment analysis, to improve the reliability of the results. Pathways with a false discovery rate of P\<0.05 were considered to indicate significantly enriched pathways.

### Pathway crosstalk analysis

Pathway crosstalk analysis was performed ([@b57-ol-0-0-11439]), to investigate the interactions among the significantly enriched pathways. The pathways with either a false discovery rate of P\>0.05 or \<3 genes were removed as selection criteria. The number of shared genes between pairwise pathways was calculated and pairwise pathways with \<2 overlapping genes were removed. The Jaccard Coefficient (JC) and the Overlap Coefficient (OC) parameters were calculated, to measure the overlap between the pathways. Specifically, JC=$\left| \frac{A \cap B}{A \cup B} \right|$, while OC=$\left| \frac{\mathbf{A} \cap \mathbf{B}}{\left. \textbf{min}( \middle| \mathbf{A} \middle| , \middle| \mathbf{B} \middle| ) \right.} \right|$, where A and B represent the gene numbers of the tested pathways. The interrelationships between pathways were visualized using Cytoscape software.

To determine the overall progression and further detect an association between two pathways, the KEGG and BioCarta databases were used to identify the upstream or downstream associations between pathways. Furthermore, the nodal degree was calculated using Centiscape ([@b58-ol-0-0-11439]) to identify key nodes. According to Han *et al* ([@b59-ol-0-0-11439]), key nodes are considered as those with a nodal degree ≥5.

### Integration of the PPI network

The PPI network ([@b60-ol-0-0-11439]) was used to identify key proteins for the four phases of CC. As Protein Interaction Network Analysis (PINA) (<https://omics.bjcancer.org/pina/>) ([@b61-ol-0-0-11439]) is an integrated platform for protein interaction network construction, analysis and visualization, it can identify the associations between the queried genes based on integration of data from six public PPI databases: IntAct ([@b62-ol-0-0-11439]), MINT ([@b63-ol-0-0-11439]), BioGRID ([@b64-ol-0-0-11439]), DIP ([@b65-ol-0-0-11439]), HPRD ([@b66-ol-0-0-11439]) and MIPS MPact ([@b67-ol-0-0-11439]). Thus, the PINA4MS plug-in for Cytoscape software was used to construct the PPI network, to identify CC progression-associated genes. As PINA4MS requires UniProt accession numbers, the UniProt Retrieve/ID mapping tool (<https://www.uniprot.org/uploadlists/>) was used to input gene symbols. The key nodes for the PPI network were also extracted using a criterion of nodal degree ≥5.

### Comprehensive gene-pathway analysis

To determine the molecular mechanisms and associations between the key genes and pathways, the gene-pathway network was constructed by examining the key pathways, in order to determine which pathway contained at least one of the key genes.

### Co-expression and survival analysis for key genes

To identify the co-expression of key genes and their impact on OS time, the LinkedOmics database ([@b68-ol-0-0-11439]) was used, which was based on TCGA ([@b69-ol-0-0-11439]). The co-expression analysis was performed using Pearson correlation and OS analysis was assessed with Cox regression method. For survival analysis, samples were divided by the median value of the investigated gene. P\<0.05 was considered to indicate a statistically significant difference for both the co-expression correlation and OS time.

Results
=======

### Identification of DEGs

Analysis of the GSE63514 dataset using GEO2R, with a criteria of ≥2 FC and P\<0.05, identified a total of 3,446 DEGs for the four phases as follows: 446 DEGs in phase I, of which 76 were upregulated and 370 were downregulaged; 382 DEGs in phase II, of which 146 were upregulated and 236 were downregulated; 756 DEGs in phase III, of which 435 were upregulated and 321 were downregulated; 1,862 DEGs in phase IV, of which 816 were upregulated and 1046 were downregulated.

### Identification of hub genes

Following removal of 2,256 irrelevant genes (Phase I, 265; Phase II, 197; Phase III, 603; Phase IV, 1191), 12 topological algorithms were used and the top 10 genes for each method were extracted. A total of 107 genes that appeared at least twice were conserved as hub genes, as presented in [Table I](#tI-ol-0-0-11439){ref-type="table"}. A total of 29 genes were identified in phase I, among which five genes were members of the kinesin family (*KIF11, KIF15, KIF23, KIF4A* and *KIF14*), and five genes were associated with meiosis and the maturation of oocytes \[*BUB1B* ([@b70-ol-0-0-11439]), *BUB1* ([@b71-ol-0-0-11439]), *CCNA2* ([@b72-ol-0-0-11439]), *CCNB1* ([@b72-ol-0-0-11439]) and *CDK1* ([@b73-ol-0-0-11439])\], as well as other genes associated with inflammation and innate immune responses \[*STAT1* ([@b74-ol-0-0-11439]), *GBP1* ([@b75-ol-0-0-11439]) and *RHOA* ([@b76-ol-0-0-11439])\]. A total of 25 hub genes were verified in phase II, among which the involvement of seven interferon-induced genes was identified (*IFI44L, IFIT3, IFIF1, IFIF5, IFI44, IFIT2* and *IFI6*), and several pattern recognition receptor-associated genes \[*IRF7* ([@b77-ol-0-0-11439]), *STAT1* ([@b78-ol-0-0-11439]) and *CXCL10* ([@b79-ol-0-0-11439])\], as well as some genes involved in invasion and metastasis of cancer cells \[*HGF* ([@b80-ol-0-0-11439]), *IGF1* ([@b81-ol-0-0-11439]), *KIT* ([@b82-ol-0-0-11439]), *FN1* ([@b83-ol-0-0-11439]) and *CXCL12* ([@b84-ol-0-0-11439])\]. A number of common cancer-associated signaling pathway genes were identified in phase III \[*CCND1* ([@b85-ol-0-0-11439]), *STAT1* ([@b86-ol-0-0-11439]) and *VEGFA* ([@b87-ol-0-0-11439])\]. A total of three C-X-C motif chemokine ligands (*CXCL8, CXCL11* and *CXCL4*), two integrin subunits (*ITGB1* and *ITGA1*), and one mitogen-activated protein (*MAPK12*) were identified in phase IV. Furthermore, *PIK3CA* ([@b88-ol-0-0-11439]) and *FOS* ([@b89-ol-0-0-11439]) participated in cancer-associated pathways in phase IV. The diversity of genes within the four phases demonstrated that CC progression is a complex process and its molecular mechanisms are not constant.

### GO enrichment analysis of hub genes

To further identify the biological functions and locations of hub genes, GO enrichment analysis ([@b90-ol-0-0-11439]) was performed ([Fig. 2](#f2-ol-0-0-11439){ref-type="fig"}). Hub genes were notably enriched in 'biological regulation', 'metabolic process' and 'cellular component organization' in phase I and II, while 'responses to stimulus' and 'biological regulation' were predominantly enriched at phases III--IV in biological process. For the cellular components, 'nucleus', 'membrane-enclosed lumen' and 'macromolecular complex' was enriched at phases I--III, while 'chromosome' and 'membrane' was identified in phases II and IV, respectively. 'Protein binding' was enriched at all four phases for Molecular Function. Furthermore, 'nucleic acid binding' and 'hydrolase activity' were enriched at phase II and III, while 'ion binding' was enriched at phase III and IV.

### Pathway enrichment analysis of hub genes

As presented in [Table II](#tII-ol-0-0-11439){ref-type="table"}, a total of 10 notably enriched pathways were identified at phase I, of which five pathways were associated with virus infections including, 'influenza A', 'tuberculosis', 'herpes simplex infection', 'viral carcinogenesis' and 'Epstein-Barr virus infection', and additional pathways involved in the 'cell cycle', 'oocyte meiosis' and 'progesterone-mediated oocyte maturation'. Furthermore, the chemokine signaling pathway was also identified in phase I. The RIG-I-like receptor and Toll-like receptor signaling pathways were identified in phase II, and are associated with pattern-recognition receptors ([@b91-ol-0-0-11439]). In addition, several pathways, including 'focal adhesion', 'Rap1 signaling pathway', 'Ras signaling pathway', 'PI3K-Akt signaling pathway' and 'Proteoglycans in cancer' were associated with invasion and metastasis ([@b92-ol-0-0-11439]--[@b96-ol-0-0-11439]). The two common cancer-associated signaling pathways 'Pathways in cancer' and 'Proteoglycans in cancer', were enriched in phase III, while 70 pathways were significant enriched at phase IV (P\<0.05). Apart from the common cancer-associated signaling pathways and virus infection pathways at phase IV, the 'IL-17 signaling pathway', 'VEGF signaling pathway' and 'endocrine resistance' also were also demonstrated to be associated with CC progression. Furthermore, the 'AGE-RAGE signaling pathway in diabetic complications' was also identified at phases II--IV.

### Pathway crosstalk analysis

The pathway crosstalk analysis results are presented in [Fig. S1](#SD1-ol-0-0-11439){ref-type="supplementary-material"}. A total of two major modules were identified in phase I, one of which was predominantly associated with inflammatory responses to viral infections, such as the NOD-like receptor signaling pathway and the chemokine signaling pathway, while the other module was associated with cycle regulation of oocytes, including cell cycle, progesterone-mediated oocyte maturation and oocyte meiosis ([Fig. S1A](#SD1-ol-0-0-11439){ref-type="supplementary-material"}). Similarly, the pathways were grouped into two modules in phase II. One module consisted of immune responses (RIG-I-like receptor and Toll-like receptor signaling pathways, and NOD-like receptor signaling pathway), which may trigger rapid activation of innate immunity by inducing the production of proinflammatory cytokines ([@b97-ol-0-0-11439]--[@b99-ol-0-0-11439]). The other module was predominantly involved in the regulation of cell proliferation and invasion (Ras signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, focal adhesion and other cancer-associated signaling pathways) ([Fig. S1B](#SD1-ol-0-0-11439){ref-type="supplementary-material"}). Notably, the two modules in phases I and II were not independent as they were demonstrated to connect with each other via several signaling pathways. All pathways formed a cluster and common cancer-associated signaling pathways were indicated to play a critical role in phase III ([Fig. S1C](#SD1-ol-0-0-11439){ref-type="supplementary-material"}), while the connection between the pathways became highly complex in phase IV ([Fig. S1D](#SD1-ol-0-0-11439){ref-type="supplementary-material"}). The possible molecular mechanisms, such as inflammation caused by virus infections, pathways associated with cell invasion, IL-17 and VEGF signaling pathways, and endocrine resistance, are associated with one another. These results further verified the complexity of CC. A comprehensive combination of pathway crosstalk analysis containing 47 nodes and 105 edges among the four phases is presented in [Fig. 3A](#f3-ol-0-0-11439){ref-type="fig"}. By analyzing the nodes with degrees ≥5, a subnetwork containing 11 key pathways was extracted ([Fig. 3B](#f3-ol-0-0-11439){ref-type="fig"}). It indicates that the MAPK signaling pathway (degree=33), PI3K-Akt signaling pathway (degree=21) and focal adhesion (degree=15), which are ranked as the top three nodes and most interactive, may play critical roles in the progression of CC.

### PPI network analysis

A PPI network containing 51 nodes and 78 edges was constructed ([Fig. 4A](#f4-ol-0-0-11439){ref-type="fig"}) by downloading the hub genes into the PINA database. Based on the description of a previous study ([@b59-ol-0-0-11439]), which defined the main nodes as nodes with degree \>5, 14 key genes were identified from the PPI network ([Fig. 4B](#f4-ol-0-0-11439){ref-type="fig"}). *CDK1, FN1* and *ITGB1* rank first, second and third, respectively, as the top three-degree levels (16, 12 and 8, respectively). *STAT1* was the only gene demonstrated to be involved at all four phases. Furthermore, *MMP9* presented self-regulating functions and was demonstrated to co-express with *FN1* and *ITGB1*.

### Comprehensive gene-pathway analysis

After mapping the key genes onto the key pathways using the KEGG and BioCarta databases, a potential gene-pathway flowchart, including eight key pathways and six key genes was constructed ([Fig. 5](#f5-ol-0-0-11439){ref-type="fig"}). The results demonstrated the following: For phase I, *CDK1* and *CCNB1* participated in the regulation of the cell cycle, while *CDK1* was also involved in viral carcinogenesis; for phases II--IV, 'pathways in cancer,' 'focal adhesion' and 'PI3K-Akt signaling pathway' were ranked the top three pathways according to the number of genes involved; *FN1, ITGB1* and *MMP9* may be associated with metastasis of tumor cells, and *STAT1* participated in 'pathways in cancer' and 'Toll-like receptor signaling pathway', which functioned at a phase IV.

### Co-expression network and survival analysis for key genes

By mining the data from LinkedOmics, the results of co-expression demonstrated that *CDK1* had a significantly positive correlation with *CCNB1* (P\<0.0001), but negative correlation with *FN1* (P=0.003) and *MMP9* (P=0.001), respectively ([Fig. 6](#f6-ol-0-0-11439){ref-type="fig"}). *CCNB1* demonstrated a significantly negative correlation with *ITGB1* (P=0.047); however, *FN1, ITGB1* and *MMP9* indicated a significantly positive correlation between each other (FN1 and ITGB1, P\<0.001; FN1 and MMP9, P\<0.0001; ITGB1 and MMP9, P=0.023). *STAT1* was significantly positively correlated with *MMP9* (P\<0.0001).

Survival analysis indicated that patients with higher *FN1* and *ITGB1* expression levels had a significantly worse OS time (*FN1*, P=0.00080; *ITGB1*, P=0.00005; [Fig. 7](#f7-ol-0-0-11439){ref-type="fig"}). However, *CDK1, CCNB1, MMP9* and *STAT1* were not demonstrated to have a significant effect on OS.

Discussion
==========

To date, the occurrence and development of CC is hypothesized to be linked with persistent HPV infection ([@b100-ol-0-0-11439]); however, the specific molecular mechanisms require further investigation. In addition, although a number of studies are examining the molecular mechanisms of CC ([@b101-ol-0-0-11439]--[@b104-ol-0-0-11439]), the detailed pathological process remains unclear.

The results of the present study indicated that *CDK1* had the highest degree, and participated in the cell cycle with *CCNB1* and viral carcinogenesis in phase I. CDK1 is one of the major cell cycle regulatory proteins and operates at the center of the cell cycle regulatory network ([@b105-ol-0-0-11439]). It regulates the G-S phase transition and initiates DNA replication ([@b106-ol-0-0-11439]). Furthermore, as a core molecule at the M phase checkpoint, *CDK1* plays a role in the regulation of G~2~ phase, at M phase in the cell cycle ([@b107-ol-0-0-11439]). The HPV infection pathway is regulated within the viral carcinogenesis pathway ([@b19-ol-0-0-11439]). E6 proteins inactivate p53 by binding ([@b108-ol-0-0-11439]), while p53 negatively regulates *CDK1* transcription under normal physiological conditions ([@b109-ol-0-0-11439]). In addition, the activation of cyclin B1-CDK1 is the key event that initiates the start of mitosis ([@b110-ol-0-0-11439]). Centrosome separation can be regulated by *CDK1* ([@b111-ol-0-0-11439]), and cyclin B1-CDK1 remains activated following centrosome separation ([@b110-ol-0-0-11439]). Hence, overexpression of *CDK1* can cause dysfunction in cell cycle progression, failure of normal proliferation and differentiation, and thereby lead to malignant proliferation of cancer cells and the formation of CC. *CCNB1* is a notable member of the cyclin family, a key initiator and a stringent quality control step of mitosis ([@b112-ol-0-0-11439]). It also plays a key role in the regulation of *CDK1*, and its phosphorylated substrates can promote the transition of the cell cycle from G~2~ to mitosis ([@b113-ol-0-0-11439],[@b114-ol-0-0-11439]). Amplification of the HPV genome depends on prolongation of the G~2~ phase in the cell cycle ([@b115-ol-0-0-11439]). *CCNB1* is a downstream target of *STAT3*, which is a key gene that regulates the proliferation and differentiation of CC cells ([@b116-ol-0-0-11439]). In cells with inactivated *STAT3, CCNB1* expression is downregulated and amplification of the HPV genome is also decreased, resulting in decreased activity of CC cells ([@b116-ol-0-0-11439]). As the results of the present study demonstrated that *CDK1* and *CCNB1* occurred in phase I and functioned as regulators of proliferation and differentiation, they may be potential promoters of CIN and CC.

In the process of tumor invasion and metastasis, cancer cells can bind to ligands of the extracellular matrix (ECM) via integrins and degrade the basement membrane (BM) by secreting proteases via the pathways of focal adhesion and the PI3K-Akt signaling pathway ([@b117-ol-0-0-11439]). This degradation is also the prerequisite for stromal infiltration and cancer cell migration ([@b118-ol-0-0-11439]). *ITGB1* belongs to the integrin family and *FN1* is the ligand. The binding of *ITGB1* and *FN1* induces the phosphorylation of tyrosine and directly affects cytoskeleton reconstruction and signal transduction activities of the Ras-MAPK signaling pathway via the *RAP1* signaling pathway, which initiates the expression of *MMP* genes ([@b119-ol-0-0-11439]). MMPs are a family of calcium and zinc-dependent proteases that degrade a variety of components of the ECM ([@b120-ol-0-0-11439]). Collagen type IV is the main scaffold in the BM of the ECM and also the main substrate of *MMP9* ([@b121-ol-0-0-11439]). *MMP9* can decompose the nestin in the BM to destroy the cells integrity and promote the invasion and metastasis of cancer cells ([@b122-ol-0-0-11439]). *MMP9* expression in HPV-positive patients with CC is higher than in HPV-negative patients ([@b123-ol-0-0-11439]). Cardeal *et al* ([@b124-ol-0-0-11439]) reported that *MMP9* is upregulated in human keratinocytes expressing the HPV16 E7 protein. This may be due to *TIMP2*, an inhibitor of *MMP9*, which could be downregulated by HPV16 E7. It was also demonstrated that HPV can directly regulate the activity of *MMP9* in lung cancer cells ([@b125-ol-0-0-11439]). There may be an association between HPV infection and the *MMP* family, which may be beneficial in the diagnosis of cervical precancerous lesions and CC as *MMP9* may be considered as a novel biomarker. However, the specific molecular mechanisms require further investigation. As FN1 and ITGB1 were targets of miR-9-3p ([@b126-ol-0-0-11439]) and FN1 promoted migration and invasion by upregulating MMP9 in cancer ([@b127-ol-0-0-11439]), it is not surprising that these three genes are co-expressed as a reaction triplet. Furthermore, since higher levels of *FN1* and *ITGB1* are significantly associated with lower OS rate, these two genes may be developed as novel prognostic factors for CC.

*STAT1*, the only gene that participates in all four phases, in the present study, is involved in the cancer pathway at phases II, III and IV. It has been reported that *STAT1* is upregulated in both CIN1 and CC ([@b128-ol-0-0-11439]), and the results of the present study that STAT1 is upregulated in phase I, III and IV confirmed this finding. A previous study demonstrated that activated *STAT1* plays a tumor suppressive role in breast cancer cells ([@b129-ol-0-0-11439]). Nevertheless, *STAT1* also exerts tumor promoter effects under specific conditions ([@b130-ol-0-0-11439]). In some malignant diseases, including breast and lung cancers, *STAT1* can act as an oncoprotein or a tumor suppressor of the same cell type based on the specific genetic background ([@b130-ol-0-0-11439]). In CC, *STAT1* may have a protective effect in the early stages of HPV infection but may act as a proto-oncogene during the invasive phase of the disease ([@b128-ol-0-0-11439]). *STAT1* can promote cancer cell death by activating p53 expression, and it plays a role in immunosurveillance, and the inhibition of angiogenesis and metastasis in cancer cells ([@b130-ol-0-0-11439]); however, *STAT1* can also promote tumor invasion and metastasis in chronic inflammation ([@b131-ol-0-0-11439]). The effect of *STAT1* in CC still remains unclear; therefore, further verification is required as it may be a key target for the treatment of CC.

The current study presented several limitations. First, as this was an *in-silico* study, the identification of DEGs may change with additional data, thus the results of subsequent analyses may change accordingly. Secondly, some genes were excluded to decrease the false-positive rate; however, these genes may also have a vital effect on CC. Thirdly, although several genes associated with HPV infection (*TP53TG1, RAC1, PAK2* and *LTBP2*) were identified in DEGs, HPV infection was not observed in the pathway analyses. This may be due to the fact that an insufficient amount of hub genes were identified, or the genes had a low or moderate effect on the HPV infection pathway.

In conclusion, the present study revealed that *CDK1, CCNB1, ITGB1, FN1, MMP9* and *STAT1* played different roles in the progression of CC through different signaling pathways. *CDK1* and *CCNB1* served as regulators of proliferation and differentiation via regulation of the cell cycle and viral tumorigenesis, and initiated CIN and CC, whereas *FN1, ITGB1* and *MMP9* were co-expressed as a reaction triplet to trigger metastasis via cancer pathways, PI3K-Akt signaling pathway and focal adhesion. *FN1* and *ITGB1* may be novel prognostic factors for CC. *STAT1* may have a protective effect in the early stage of HPV infection, but may also act as a proto-oncogene during the invasive stage; however, the specific molecular mechanisms require further investigation.
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CC

:   cervical cancer

CIN

:   cervical intraepithelial neoplasia

GO

:   Gene Ontology

PPI

:   protein-protein interaction

TCGA

:   The Cancer Genome Atlas

DEG

:   differentially expressed gene

OS

:   overall survival

STRING

:   Search Tool for the Retrieval of Interacting Genes

KEGG

:   Kyoto Encyclopedia of Genes and Genomes
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:   protein interaction network analysis

![Flow diagram of the present study. FC, fold change; DEGs, differentially expressed genes; STRING, Search Tool for the Retrieval of Interacting Genes/Proteins; GO, Gene Ontology; FDR, false discovery rate; KEGG, Kyto Encyclopedia of Genes and Genomes; PPI, protein-protein interaction.](ol-19-04-3316-g00){#f1-ol-0-0-11439}

![Gene ontology enrichment analysis of hub genes for phase I, II, III and IV. The number in each phase represents the gene count.](ol-19-04-3316-g03){#f2-ol-0-0-11439}

![Comprehensive pathways crosstalk analysis. (A) Combination of pathways crosstalk analysis for the four phases and the (B) subnetwork with nodal degree ≥5. Green, phase I; yellow, phase II; orange, phase III; red, phase IV. The arrow represents the up/downstream associations between the pathways. MAPK signaling pathway (degree=33), PI3K-Akt signaling pathway (degree=21) and Focal adhesion (degree=15) rank as the top three pathways, whereby the majority of other pathways transfer information with them.](ol-19-04-3316-g04){#f3-ol-0-0-11439}

![Protein-protein interaction network analysis. (A) Protein-protein interaction network downloaded from The Protein Interaction Network Analysis platform and (B) subnetwork with nodal degree ≥5. Green, phase I; blue, phase II; yellow, phase II; red, phase IV. The nodal size represents the degree of each node. CDK1 (degree=16), FN1 (degree=12) and ITGB1 (degree=8) rank as the top three proteins. MMP9 was self-regulated and co-expressed with FN1 and ITGB1.](ol-19-04-3316-g05){#f4-ol-0-0-11439}

![Gene-pathway flowchart for the key genes and the pathways in phases I--IV. Circle, gene; rectangle, pathway. CDK1 and CCNB1 regulate the cell cycle and they are activated in phase I. For phases II--IV, 'pathways in cancer', 'focal adhesion' and 'PI3K-Akt signaling pathway' rank as the top three pathways according to the number of genes involved.](ol-19-04-3316-g06){#f5-ol-0-0-11439}

![Co-expression analyses for the key genes. Positive correlation was detected between CDK1 and CCNB1; between FN1 and ITGB1, and MMP9, and between STAT1 and MMP9. Color in each grid represents the correlation coefficient between two genes. The values in the color legend represent the correlation coefficient. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001.](ol-19-04-3316-g07){#f6-ol-0-0-11439}

![Survival analysis for the key genes. (A) FN1, (B) ITGB1, (C) CDK1 and (D) CCNB1, (E) MMP9 and (F) STAT1. ITGB1 and FN1 have significant effect on overall survival.](ol-19-04-3316-g08){#f7-ol-0-0-11439}

###### 

Hub genes in phases I--IV.

  Phase       Gene       Regulation   Counts   LogFC   P-value
  ----------- ---------- ------------ -------- ------- ---------
  Phase I     CDK1       \+           7        1.24    \<0.01
              KIF11      \+           7        1.27    0.01
              BUB1B      \+           6        1.13    0.02
              BUB1       \+           5        1.17    0.01
              CCNA2      \+           5        1.01    \<0.01
              HLA-DPA1   \+           5        1.49    0.03
              CENPE      \+           5        1.36    0.02
              RHOA       \+           4        1.47    \<0.01
              KIF15      \+           4        1.11    \<0.01
              CCNB1      \+           4        1.23    0.01
              NDC80      \+           4        1.47    0.01
              TTK        \+           4        1.14    \<0.01
              STAT1      --           4        −1.47   0.03
              CXCL10     \+           4        2.47    \<0.01
              KIF23      \+           4        1.48    0.01
              KIF4A      \+           3        1.00    0.05
              PSMB9      \+           3        1.12    0.03
              GNG2       \+           3        1.26    0.04
              SPAG5      \+           2        1.15    0.01
              TRIP13     \+           2        1.09    0.02
              ANLN       \+           2        1.19    0.02
              CDKN3      \+           2        1.83    \<0.01
              KIF14      \+           2        1.15    0.01
              MKI67      \+           2        1.45    0.01
              NUSAP1     \+           2        1.22    0.02
              NEK2       \+           2        1.30    0.01
              NCAPG      \+           2        1.18    \<0.01
              DLGAP5     \+           2        1.54    \<0.01
              GBP1       \+           2        1.45    \<0.01
  Phase II    STAT1      --           9        −1.03   0.02
              CXCL10     --           6        −2.16   0.02
              CXCL12     --           6        −1.48   0.04
              DCN        --           6        −1.37   0.01
              CCL2       --           5        −1.54   0.01
              KIT        --           5        −1.26   0.05
              IGF1       --           5        −1.86   \<0.01
              OAS2       --           4        −1.37   0.01
              IRF7       --           4        −1.08   0.01
              ISG15      --           4        −1.83   0.02
              FN1        --           4        −1.34   0.04
              HGF        --           4        −1.22   0.02
              HERC6      --           3        −1.71   \<0.01
              MX2        --           3        −1.86   0.01
              IFIT3      --           3        −1.79   \<0.01
              IFIT1      --           3        −2.96   \<0.01
              GBP1       --           3        −1.20   0.01
              CDC6       \+           3        1.40    0.01
              IFIT5      --           2        −1.11   \<0.01
              IFI6       --           2        −1.55   0.01
              SP110      --           2        −1.43   \<0.01
              IFI44      --           2        −1.87   \<0.01
              DDX60      --           2        −1.18   \<0.01
              IFIT2      --           2        −1.67   \<0.01
              RSAD2      --           2        −2.66   \<0.01
  Phase III   BIRC5      \+           9        1.13    \<0.01
              TOP2A      \+           8        1.36    \<0.01
              KIF2C      \+           6        1.04    \<0.01
              MCM10      \+           6        1.16    0.01
              VEGFA      \+           6        1.27    \<0.01
              MAD2L1     \+           5        1.03    \<0.01
              KIF15      \+           5        1.45    \<0.01
              ASPM       \+           5        1.70    \<0.01
              FOXM1      \+           5        1.18    0.01
              MX2        \+           4        1.34    0.01
              STAT1      \+           4        1.20    \<0.01
              PLXNA4     --           4        −1.15   0.01
              AR         --           4        −1.69   \<0.01
              CCND1      --           3        1.20    \<0.01
              OAS2       \+           3        1.05    \<0.01
              ACLY       \+           3        1.55    0.01
              GNG2       \+           3        −1.21   \<0.01
              RSAD2      \+           2        1.85    \<0.01
              ISG15      \+           2        1.82    \<0.01
              IFI35      \+           2        1.35    0.01
              IRF5       \+           2        1.46    \<0.01
              SAMHD1     \+           2        1.05    \<0.01
              MKI67      \+           2        1.20    \<0.01
              PLK4       \+           2        1.03    0.01
              AHCTF1     \+           2        1.03    \<0.01
              NUDC       \+           2        1.07    \<0.01
              EXO1       \+           2        1.29    \<0.01
              PLXNA3     \+           2        1.01    0.01
              MMP9       \+           2        2.55    \<0.01
              PLAUR      \+           2        1.01    \<0.01
  Phase IV    PIK3CA     \+           9        1.42    \<0.01
              CXCL8      \+           8        1.28    0.05
              ITGB1      \+           8        2.20    \<0.01
              PTK2       \+           8        1.33    \<0.01
              GNG2       \+           6        1.18    0.05
              ITGA1      \+           6        1.33    \<0.01
              GNG12      --           6        −1.14   \<0.01
              FOS        --           5        −1.13   0.05
              EDN1       \+           5        1.07    \<0.01
              NMU        --           4        −2.23   \<0.01
              LPAR5      --           4        −1.36   \<0.01
              STAT1      \+           3        1.75    \<0.01
              FN1        \+           3        3.61    \<0.01
              GSTM1      --           3        −1.09   0.02
              PLA2G4A    --           3        −1.41   0.02
              CXCR4      \+           2        1.58    \<0.01
              HCAR3      --           2        −1.60   \<0.01
              S1PR5      --           2        −1.56   \<0.01
              CXCL5      --           2        −2.10   0.01
              NQO1       --           2        −1.38   0.01
              CXCL11     \+           2        1.69    0.02
              COMP       \+           2        1.62    0.01
              MAPK12     \+           2        1.38    \<0.01

+, upregulated; -, downregulated.

###### 

Pathway enrichment analysis for phases I--IV.

  Phase       Pathway                                                                                                                     FDR       Involved genes
  ----------- --------------------------------------------------------------------------------------------------------------------------- --------- ------------------------------------------------------------------------
  Phase I     Cell cycle                                                                                                                  \<0.001   CDK1, TTK, CCNA2, BUB1, CCNB1, BUB1B
              Progesterone-mediated oocyte maturation                                                                                     0.002     CDK1, CCNA2, BUB1, CCNB1
              Chemokine signaling pathway                                                                                                 0.006     RHOA, CXCL10, STAT1, GNG2
              Oocyte meiosis                                                                                                              0.018     CDK1, BUB1, CCNB1
              NOD-like receptor signaling pathway                                                                                         0.036     RHOA, GBP1, STAT1
              Influenza A                                                                                                                 0.036     HLA-DPA1, CXCL10, STAT1
              Tuberculosis                                                                                                                0.037     RHOA, HLA-DPA1, STAT1
              Herpes simplex infection                                                                                                    0.038     CDK1, HLA-DPA1, STAT1
              Viral carcinogenesis                                                                                                        0.044     RHOA, CDK1, CCNA2
              Epstein-Barr virus infection                                                                                                0.044     CDK1, HLA-DPA1, CCNA2
  Phase II    Influenza A                                                                                                                 \<0.001   CCL2, OAS2, IRF7, RSAD2, CXCL10, STAT1
              NOD-like receptor signaling pathway                                                                                         \<0.001   GBP1, CCL2, OAS2, IRF7, STAT1
              Herpes simplex infection                                                                                                    \<0.001   CCL2, OAS2, IRF7, IFIT1, STAT1
              Pathways in cancer                                                                                                          0.001     HGF, IGF1, FN1, KIT, CXCL12, STAT1
              Hepatitis C                                                                                                                 0.001     OAS2, IRF7, IFIT1, STAT1
              Cytokine-cytokine receptor interaction                                                                                      0.001     HGF, CCL2, KIT, CXCL10, CXCL12
              RIG-I-like receptor signaling pathway                                                                                       0.003     IRF7, ISG15, CXCL10
              Chemokine signaling pathway                                                                                                 0.003     CCL2, CXCL10, CXCL12, STAT1
              Genes encoding secreted soluble factors                                                                                     0.003     HGF, CCL2, IGF1, CXCL10, CXCL12
              Proteoglycans in cancer                                                                                                     0.004     HGF, IGF1, FN1, DCN
              AGE-RAGE signaling pathway in diabetic complications                                                                        0.005     CCL2, FN1, STAT1
              Toll-like receptor signaling pathway                                                                                        0.006     IRF7, CXCL10, STAT1
              Ensemble of genes encoding extracellular matrix and extracellular matrix-associated proteins                                0.008     HGF, CCL2, IGF1, FN1, DCN, CXCL10, CXCL12
              Measles                                                                                                                     0.009     OAS2, IRF7, STAT1
              PI3K-Akt signaling pathway                                                                                                  0.015     HGF, IGF1, FN1, KIT
              Focal adhesion                                                                                                              0.024     HGF, IGF1, FN1
              Rap1 signaling pathway                                                                                                      0.026     HGF, IGF1, KIT
              Ras signaling pathway                                                                                                       0.029     HGF, IGF1, KIT
              Ensemble of genes encoding ECM-associated proteins including ECM-affilaited proteins, ECM regulators and secreted factors   0.032     HGF, CCL2, IGF1, CXCL10, CXCL12
  Phase III   Pathways in cancer                                                                                                          0.002     BIRC5, CCND1, MMP9, AR, STAT1, GNG2, VEGFA
              Bladder cancer                                                                                                              0.006     CCND1, MMP9, VEGFA
              Hepatitis B                                                                                                                 0.011     BIRC5, CCND1, MMP9, STAT1
              Pancreatic cancer                                                                                                           0.012     CCND1, STAT1, VEGFA
              Proteoglycans in cancer                                                                                                     0.025     PLAUR, CCND1, MMP9, VEGFA
              AGE-RAGE signaling pathway in diabetic complications                                                                        0.027     CCND1, STAT1, VEGFA
  Phase IV    Chemokine signaling pathway                                                                                                 \<0.001   GNG12, CXCL11, CXCL5, PIK3CA, CXCR4, PTK2, STAT1, CXCL8, GNG2
              Pathways in cancer                                                                                                          \<0.001   FN1, LPAR5, GNG12, ITGB1, PIK3CA, CXCR4, FOS, PTK2, STAT1, CXCL8, GNG2
              Fluid shear stress and atherosclerosis                                                                                      \<0.001   GSTM1, NQO1, MAPK12, PIK3CA, FOS, EDN1, PTK2
              Signaling of Hepatocyte Growth Factor Receptor                                                                              \<0.001   ITGA1, ITGB1, PIK3CA, FOS, PTK2
              PI3K-Akt signaling pathway                                                                                                  \<0.001   ITGA1, FN1, COMP, LPAR5, GNG12, ITGB1, PIK3CA, PTK2, GNG2
              B Cell Survival Pathway                                                                                                     \<0.001   ITGA1, ITGB1, PIK3CA, FOS
              AGE-RAGE signaling pathway in diabetic complications                                                                        \<0.001   MAPK12, FN1, PIK3CA, EDN1, STAT1, CXCL8
              Toll-like receptor signaling pathway                                                                                        \<0.001   MAPK12, CXCL11, PIK3CA, FOS, STAT1, CXCL8
              Aspirin Blocks Signaling Pathway Involved in Platelet Activation                                                            \<0.001   PLA2G4A, ITGA1, ITGB1, PTK2
              Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia                                                 \<0.001   ITGA1, ITGB1, PIK3CA, PTK2
              Pertussis                                                                                                                   \<0.001   MAPK12, CXCL5, ITGB1, FOS, CXCL8
              Focal adhesion                                                                                                              \<0.001   ITGA1, FN1, COMP, ITGB1, PIK3CA, PTK2
              TNF signaling pathway                                                                                                       \<0.001   MAPK12, CXCL5, PIK3CA, FOS, EDN1
              Leukocyte transendothelial migration                                                                                        \<0.001   MAPK12, ITGB1, PIK3CA, CXCR4, PTK2
              Regulation of actin cytoskeleton                                                                                            \<0.001   ITGA1, FN1, GNG12, TGB1, PIK3CA, PTK2
              VEGF signaling pathway                                                                                                      \<0.001   PLA2G4A, MAPK12, PIK3CA, PTK2
              PTEN dependent cell cycle arrest and apoptosis                                                                              \<0.001   ITGB1, PIK3CA, PTK2
              uCalpain and friends in Cell spread                                                                                         \<0.001   ITGA1, ITGB1, PTK2
              Trefoil Factors Initiate Mucosal Healing                                                                                    \<0.001   ITGB1, PIK3CA, PTK2
              Prolactin signaling pathway                                                                                                 \<0.001   MAPK12, PIK3CA, FOS, STAT1
              Leishmaniasis                                                                                                               \<0.001   MAPK12, ITGB1, FOS, STAT1
              Inhibition of Cellular Proliferation by Gleevec                                                                             \<0.001   PIK3CA, FOS, STAT1
              CXCR4 Signaling Pathway                                                                                                     \<0.001   PIK3CA, CXCR4, PTK2
              TPO Signaling Pathway                                                                                                       \<0.001   PIK3CA, FOS, STAT1
              Bacterial invasion of epithelial cells                                                                                      \<0.001   FN1, ITGB1, PIK3CA, PTK2
              mCalpain and friends in Cell motility                                                                                       \<0.001   ITGA1, ITGB1, PTK2
              ECM-receptor interaction                                                                                                    \<0.001   ITGA1, FN1, COMP, ITGB1
              Small cell lung cancer                                                                                                      \<0.001   FN1, ITGB1, PIK3CA, PTK2
              EGF Signaling Pathway                                                                                                       \<0.001   PIK3CA, FOS, STAT1
              IL-17 signaling pathway                                                                                                     \<0.001   MAPK12, CXCL5, FOS, CXCL8
              PDGF Signaling Pathway                                                                                                      \<0.001   PIK3CA, FOS, STAT1
              Amoebiasis                                                                                                                  \<0.001   FN1, PIK3CA, PTK2, CXCL8
              Endocrine resistance                                                                                                        \<0.001   MAPK12, PIK3CA, FOS, PTK2
              Proteoglycans in cancer                                                                                                     \<0.001   MAPK12, FN1, ITGB1, PIK3CA, PTK2
              Chagas disease (American trypanosomiasis)                                                                                   \<0.001   MAPK12, PIK3CA, FOS, CXCL8
              Agrin in Postsynaptic Differentiation                                                                                       \<0.001   ITGA1, ITGB1, PTK2
              Integrin Signaling Pathway                                                                                                  \<0.001   ITGA1, ITGB1, PTK2
              Fc Epsilon Receptor I Signaling in Mast Cells                                                                               \<0.001   PLA2G4A, PIK3CA, FOS
              Cholinergic synapse                                                                                                         \<0.001   GNG12, PIK3CA, FOS, GNG2
              Platelet activation                                                                                                         0.001     PLA2G4A, MAPK12, ITGB1, PIK3CA
              Osteoclast differentiation                                                                                                  0.001     MAPK12, PIK3CA, FOS, STAT1
              Dopaminergic synapse                                                                                                        0.001     MAPK12, GNG12, FOS, GNG2
              Hepatitis C                                                                                                                 0.001     MAPK12, PIK3CA, STAT1, CXCL8
              Cytokine-cytokine receptor interaction                                                                                      0.001     CXCL11, CXCL5, CXCR4, ACKR3, CXCL8
              Hepatitis B                                                                                                                 0.001     PIK3CA, FOS, STAT1, CXCL8
              Phospholipase D signaling pathway                                                                                           0.001     PLA2G4A, LPAR5, PIK3CA, CXCL8
              Shigellosis                                                                                                                 0.001     MAPK12, ITGB1, CXCL8
              Fc epsilon RI signaling pathway                                                                                             0.002     PLA2G4A, MAPK12, PIK3CA
              Influenza A                                                                                                                 0.002     MAPK12, PIK3CA, STAT1, CXCL8
              Axon guidance                                                                                                               0.002     ITGB1, PIK3CA, CXCR4, PTK2
              Integrin Signaling Pathway                                                                                                  0.002     ITGA1, PIK3CA, PTK2
              Salmonella infection                                                                                                        0.003     MAPK12, FOS, CXCL8
              MAPKinase Signaling Pathway                                                                                                 0.003     MAPK12, FOS, STAT1
              Rap1 signaling pathway                                                                                                      0.003     MAPK12, LPAR5, ITGB1, PIK3CA
              Rheumatoid arthritis                                                                                                        0.003     CXCL5, FOS, CXCL8
              Th1 and Th2 cell differentiation                                                                                            0.003     MAPK12, FOS, STAT1
              Circadian entrainment                                                                                                       0.003     GNG12, FOS, GNG2
              Inflammatory mediator regulation of TRP channels                                                                            0.003     PLA2G4A, MAPK12, PIK3CA
              Ras signaling pathway                                                                                                       0.003     PLA2G4A, GNG12, PIK3CA, GNG2
              Choline metabolism in cancer                                                                                                0.003     PLA2G4A, PIK3CA, FOS
              Retrograde endocannabinoid signaling                                                                                        0.003     MAPK12,GNG12,GNG2
              T cell receptor signaling pathway                                                                                           0.004     MAPK12, PIK3CA, FOS
              Th17 cell differentiation                                                                                                   0.004     MAPK12, FOS, STAT1
              Serotonergic synapse                                                                                                        0.004     PLA2G4A, GNG12, GNG2
              Toxoplasmosis                                                                                                               0.004     MAPK12, ITGB1, STAT1
              Glutamatergic synapse                                                                                                       0.004     PLA2G4A, GNG12, GNG2
              MAPK signaling pathway                                                                                                      0.004     PLA2G4A, MAPK12, GNG12, FOS
              Sphingolipid signaling pathway                                                                                              0.005     S1PR5, MAPK12, PIK3CA
              NOD-like receptor signaling pathway                                                                                         0.012     MAPK12, STAT1, CXCL8
              cAMP signaling pathway                                                                                                      0.018     HCAR3, PIK3CA, FOS

FDR, false discovery rate.
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